Literature DB >> 19368810

Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases.

Guo Nan Yin1, Ho Won Lee, Je-Yoel Cho, Kyoungho Suk.   

Abstract

Neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD), are characterized by progressive loss of cognitive function, dementia, and problems with movements. In order to find new protein biomarkers of high specificity from cerebrospinal fluid (CSF) of AD and PD patients, one-dimensional gel electrophoresis (1-DE) coupled with liquid chromatography-tandem mass spectrometry (LC-MS/MS) as well as 2-DE analysis were performed. In 1-DE and LC-MS/MS 371 proteins were identified, among which levels of proteins such as isoform 1 of contactin-1, contactin-2, carnosine dipeptidase 1 (CNDP1), 120 kDa isoform precursor of neural cell adhesion molecule 1 (NCAM-120), alpha-dystroglycan, secreted protein acidic and rich in cysteine-like protein 1 precursor (SPARCL1), isoform 2 of calsyntenin 1 (CLSTN1), and neuronal pentraxin receptor (NPR) showed significant changes in AD or PD CSF compared with normal subjects. In 2-DE analysis approximately 747-915 spots were detected in CSF of AD or PD patients, from which 17-24 proteins with more than a 1.2 fold change were identified by tandem MS. Most proteins identified showed consistent changes in LC-MS/MS and 2-DE analysis. Three proteins that showed significant changes were selected for further validation by Western blot analysis. While NCAM-120 and alpha-dystroglycan exhibited higher levels in both AD and PD CSF compared with normal subjects, the level of NPR was increased only in AD CSF in Western blot analysis. The results were consistent with quantitative analysis of 2-DE spots. A higher level of NPR was also found in AD serum. This study suggests that NCAM-120, alpha-dystroglycan, and NPR are candidate biomarkers in CSF for neurodegenerative diseases, and that the changes in the CSF level of NPR may be specific for AD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19368810     DOI: 10.1016/j.brainres.2009.01.058

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  49 in total

1.  Alzheimer's disease clinical trials: changing the paradigm.

Authors:  Jeffrey L Cummings
Journal:  Curr Psychiatry Rep       Date:  2011-12       Impact factor: 5.285

2.  Quantitative Proteomic Profiling of Cerebrospinal Fluid to Identify Candidate Biomarkers for Alzheimer's Disease.

Authors:  Gajanan Sathe; Chan Hyun Na; Santosh Renuse; Anil K Madugundu; Marilyn Albert; Abhay Moghekar; Akhilesh Pandey
Journal:  Proteomics Clin Appl       Date:  2019-01-25       Impact factor: 3.494

3.  Proteomic analysis of cerebrospinal fluid in canine cervical spondylomyelopathy.

Authors:  Paula Martin-Vaquero; Ronaldo C da Costa; Matthew J Allen; Sarah A Moore; Jeremy K Keirsey; Kari B Green
Journal:  Spine (Phila Pa 1976)       Date:  2015-05-01       Impact factor: 3.468

Review 4.  Apolipoprotein A-I: insights from redox proteomics for its role in neurodegeneration.

Authors:  Jeriel T R Keeney; Aaron M Swomley; Sarah Förster; Jessica L Harris; Rukhsana Sultana; D Allan Butterfield
Journal:  Proteomics Clin Appl       Date:  2013-01       Impact factor: 3.494

5.  Calsyntenins function as synaptogenic adhesion molecules in concert with neurexins.

Authors:  Ji Won Um; Gopal Pramanik; Ji Seung Ko; Min-Young Song; Dongmin Lee; Hyun Kim; Kang-Sik Park; Thomas C Südhof; Katsuhiko Tabuchi; Jaewon Ko
Journal:  Cell Rep       Date:  2014-03-06       Impact factor: 9.423

Review 6.  Neuroinflammation in Alzheimer's disease: Pleiotropic roles for cytokines and neuronal pentraxins.

Authors:  Ashley Swanson; Tovah Wolf; Alli Sitzmann; Auriel A Willette
Journal:  Behav Brain Res       Date:  2018-02-17       Impact factor: 3.332

Review 7.  Proteomics in Human Parkinson's Disease: Present Scenario and Future Directions.

Authors:  Anubhuti Dixit; Rachna Mehta; Abhishek Kumar Singh
Journal:  Cell Mol Neurobiol       Date:  2019-06-12       Impact factor: 5.046

8.  Processing of the matricellular protein hevin in mouse brain is dependent on ADAMTS4.

Authors:  Matt S Weaver; Gail Workman; Marina Cardo-Vila; Wadih Arap; Renata Pasqualini; E Helene Sage
Journal:  J Biol Chem       Date:  2009-12-15       Impact factor: 5.157

9.  Cerebrospinal fluid biomarkers for dementia with lewy bodies.

Authors:  Elizabeta B Mukaetova-Ladinska; Rachael Monteith; Elaine K Perry
Journal:  Int J Alzheimers Dis       Date:  2010-10-17

10.  Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects.

Authors:  Chera L Maarouf; Thomas G Beach; Charles H Adler; Holly A Shill; Marwan N Sabbagh; Terence Wu; Douglas G Walker; Tyler A Kokjohn; Alex E Roher
Journal:  Neurol Res       Date:  2012-09       Impact factor: 2.448

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.